Ultragenyx Pharmaceutical Inc. (RARE) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Ultragenyx Pharmaceutical Inc. on June 24, 2022. The filing details the outcomes of four proposals submitted to shareholders, including the election of directors, ratification of the auditor, and advisory votes on executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
As of the record date of April 26, 2022, 69,871,583 shares were outstanding, with 67,140,757 shares represented at the meeting. The following proposals were approved:
- Proposal 1 (Election of Class III Directors): All three nominees (Lars Ekman, Matthew K. Fust, and Amrit Ray) were elected. Votes for ranged from approximately 63.1 million to 64.4 million.
- Proposal 2 (Ratification of Auditor): Stockholders ratified the selection of Ernst & Young LLP for the fiscal year ending December 31, 2022, with 66,724,191 votes for and 406,563 votes against.
- Proposal 3 (Say-on-Pay): The advisory vote to approve executive compensation passed with 57,125,366 votes for and 7,592,307 votes against.
- Proposal 4 (Frequency of Say-on-Pay): Stockholders voted to hold future advisory votes on executive compensation annually (One Year), with 64,214,557 votes for the one-year option.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class III directors, who will serve until the 2025 Annual Meeting.
- Confirm the continued engagement of Ernst & Young LLP as the independent auditor for the 2022 fiscal year.
- Note the shareholder preference for annual advisory votes on executive compensation.
- Review the significant number of votes against the Say-on-Pay proposal (approx. 7.6 million) relative to the total votes cast.